Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

van Tilburg CM, Milde T, Witt R, Ecker J, Hielscher T, Seitz A, Schenk JP, Buhl JL, Riehl D, Frühwald MC, Pekrun A, Rossig C, Wieland R, Flotho C, Kordes U, Gruhn B, Simon T, Linderkamp C, Sahm F, Taylor L, Freitag A, Burhenne J, Foerster KI, Meid AD, Pfister SM, Karapanagiotou-Schenkel I, Witt O.

Clin Epigenetics. 2019 Dec 10;11(1):188. doi: 10.1186/s13148-019-0775-1.

2.

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.

Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, Cazzaniga G, Colombini A, Flotho C, Kuhlen M, Lang P, Lauten M, Linderkamp C, Locatelli F, Lo Nigro L, Möricke A, Niggli F, Panzer-Grümayer R, Parasole R, Peters C, Caterina Putti M, Rizzari C, Suttorp M, Valsecchi MG, Conter V, Schrappe M; on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group.

Leukemia. 2019 Dec 5. doi: 10.1038/s41375-019-0670-y. [Epub ahead of print] No abstract available.

PMID:
31806872
3.

Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.

Pearson S, Guo B, Pierce A, Azadbakht N, Brazzatti JA, Patassini S, Mulero-Navarro S, Meyer S, Flotho C, Gelb BD, Whetton AD.

J Proteome Res. 2020 Jan 3;19(1):194-203. doi: 10.1021/acs.jproteome.9b00495. Epub 2019 Nov 12.

PMID:
31657576
4.

Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study.

Testi AM, Attarbaschi A, Valsecchi MG, Möricke A, Cario G, Niggli F, Silvestri D, Bader P, Kuhlen M, Parasole R, Putti MC, Lang P, Flotho C, Mann G, Rizzari C, Barisone E, Locatelli F, Linderkamp C, Lauten M, Suttorp M, Zimmermann M, Basso G, Biondi A, Conter V, Schrappe M; AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group.

Eur J Cancer. 2019 Nov;122:61-71. doi: 10.1016/j.ejca.2019.09.004. Epub 2019 Oct 17.

PMID:
31629941
5.

Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making.

Hofmans M, Schröder R, Lammens T, Flotho C, Niemeyer C, Van Roy N, Decaluwe W, Philippé J, De Moerloose B.

Br J Haematol. 2019 Nov;187(4):E83-E86. doi: 10.1111/bjh.16191. Epub 2019 Oct 15. No abstract available.

PMID:
31617209
6.

Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.

Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A.

Leukemia. 2020 Jan;34(1):151-166. doi: 10.1038/s41375-019-0541-6. Epub 2019 Aug 20.

PMID:
31431735
7.

Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Flotho C.

Epigenetics. 2019 Mar;14(3):236-244. doi: 10.1080/15592294.2019.1583039. Epub 2019 Mar 8.

PMID:
30773984
8.

Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.

Krombholz CF, Gallego-Villar L, Sahoo SS, Panda PK, Wlodarski MW, Aumann K, Hartmann M, Lipka DB, Daskalakis M, Plass C, Niemeyer CM, Erlacher M, Flotho C.

Leukemia. 2019 Jul;33(7):1805-1810. doi: 10.1038/s41375-018-0343-2. Epub 2019 Jan 24. No abstract available.

PMID:
30679798
9.

Juvenile myelomonocytic leukemia: who's the driver at the wheel?

Niemeyer CM, Flotho C.

Blood. 2019 Mar 7;133(10):1060-1070. doi: 10.1182/blood-2018-11-844688. Epub 2019 Jan 22. Review.

PMID:
30670449
10.

The long non-coding RNA landscape in juvenile myelomonocytic leukemia.

Hofmans M, Lammens T, Helsmoortel HH, Bresolin S, Cavé H, Flotho C, Hasle H, van den Heuvel-Eibrink MM, Niemeyer C, Stary J, Van Roy N, Van Vlierberghe P, Philippé J, De Moerloose B.

Haematologica. 2018 Nov;103(11):e501-e504. doi: 10.3324/haematol.2018.189977. Epub 2018 Jun 1. No abstract available.

11.

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.

Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, Nöllke P, Fischer A, Brocks D, Gu Z, Park J, Strahm B, Wlodarski M, Yoshimi A, Claus R, Lübbert M, Busch H, Boerries M, Hartmann M, Schönung M, Kilik U, Langstein J, Wierzbinska JA, Pabst C, Garg S, Catalá A, De Moerloose B, Dworzak M, Hasle H, Locatelli F, Masetti R, Schmugge M, Smith O, Stary J, Ussowicz M, van den Heuvel-Eibrink MM, Assenov Y, Schlesner M, Niemeyer C, Flotho C, Plass C.

Nat Commun. 2017 Dec 19;8(1):2126. doi: 10.1038/s41467-017-02177-w.

12.

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML.

Nat Commun. 2017 Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9.

13.

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.

Flotho C, Sommer S, Lübbert M.

Semin Cancer Biol. 2018 Aug;51:68-79. doi: 10.1016/j.semcancer.2017.10.011. Epub 2017 Nov 9. Review.

14.

Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the β-like globin locus in juvenile myelomonocytic leukemia.

Fluhr S, Krombholz CF, Meier A, Epting T, Mücke O, Plass C, Niemeyer CM, Flotho C.

Epigenetics. 2017 Aug;12(8):715-723. doi: 10.1080/15592294.2017.1356959. Epub 2017 Jul 27.

15.

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.

Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23.

PMID:
28111878
16.

Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants.

Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A, Niewisch M, Ripperger T, Göhring G, Baumann I, Schwarz S, Strahm B, Flotho C, Skoda RC, Niemeyer CM, Wlodarski MW.

Leukemia. 2017 Mar;31(3):759-762. doi: 10.1038/leu.2016.342. Epub 2016 Nov 23. No abstract available.

PMID:
27876779
17.

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.

Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R.

Oncotarget. 2016 Aug 23;7(34):55395-55408. doi: 10.18632/oncotarget.10577.

18.

CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.

Fluhr S, Boerries M, Busch H, Symeonidi A, Witte T, Lipka DB, Mücke O, Nöllke P, Krombholz CF, Niemeyer CM, Plass C, Flotho C.

Clin Epigenetics. 2016 May 5;8:50. doi: 10.1186/s13148-016-0216-3. eCollection 2016.

19.

LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19.

Helsmoortel HH, De Moerloose B, Pieters T, Ghazavi F, Bresolin S, Cavé H, de Vries A, de Haas V, Flotho C, Labarque V, Niemeyer C, De Paepe P, Van Roy N, Stary J, van den Heuvel-Eibrink MM, Benoit Y, Schulte J, Goossens S, Berx G, Haigh JJ, Speleman F, Van Vlierberghe P, Lammens T.

Haematologica. 2016 Jun;101(6):e240-4. doi: 10.3324/haematol.2016.143818. Epub 2016 Mar 11. No abstract available.

20.

Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.

Wilhelm T, Lipka DB, Witte T, Wierzbinska JA, Fluhr S, Helf M, Mücke O, Claus R, Konermann C, Nöllke P, Niemeyer CM, Flotho C, Plass C.

Epigenetics. 2016;11(2):110-9. doi: 10.1080/15592294.2016.1145327. Epub 2016 Feb 18.

21.

Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-/-γc-/- mice.

Krombholz CF, Aumann K, Kollek M, Bertele D, Fluhr S, Kunze M, Niemeyer CM, Flotho C, Erlacher M.

Haematologica. 2016 May;101(5):597-606. doi: 10.3324/haematol.2015.138545. Epub 2016 Feb 17.

22.

Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.

Cseh AM, Niemeyer CM, Yoshimi A, Catala A, Frühwald MC, Hasle H, van den Heuvel-Eibrink MM, Lauten M, De Moerloose B, Smith OP, Bernig T, Gruhn B, Kulozik AE, Metzler M, Olcay L, Suttorp M, Furlan I, Strahm B, Flotho C.

Br J Haematol. 2016 Mar;172(6):930-6. doi: 10.1111/bjh.13915. Epub 2016 Jan 13.

PMID:
26766110
23.

LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia.

Helsmoortel HH, Bresolin S, Lammens T, Cavé H, Noellke P, Caye A, Ghazavi F, de Vries A, Hasle H, Labarque V, Masetti R, Stary J, van den Heuvel-Eibrink MM, Philippé J, Van Roy N, Benoit Y, Speleman F, Niemeyer C, Flotho C, Basso G, Te Kronnie G, Van Vlierberghe P, De Moerloose B.

Blood. 2016 Mar 3;127(9):1163-72. doi: 10.1182/blood-2015-09-667808. Epub 2015 Dec 28.

PMID:
26712910
24.

Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.

Cseh A, Niemeyer CM, Yoshimi A, Dworzak M, Hasle H, van den Heuvel-Eibrink MM, Locatelli F, Masetti R, Schmugge M, Groß-Wieltsch U, Candás A, Kulozik AE, Olcay L, Suttorp M, Furlan I, Strahm B, Flotho C.

Blood. 2015 Apr 2;125(14):2311-3. doi: 10.1182/blood-2015-01-619734. No abstract available.

25.

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A.

Haematologica. 2015 Jan;100(1):17-22. doi: 10.3324/haematol.2014.109892.

26.

RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.

Poetsch AR, Lipka DB, Witte T, Claus R, Nöllke P, Zucknick M, Olk-Batz C, Fluhr S, Dworzak M, De Moerloose B, Starý J, Zecca M, Hasle H, Schmugge M, van den Heuvel-Eibrink MM, Locatelli F, Niemeyer CM, Flotho C, Plass C.

Epigenetics. 2014 Sep;9(9):1252-60. doi: 10.4161/epi.29941. Epub 2014 Jul 31.

27.

Tracing the development of acute myeloid leukemia in CBL syndrome.

Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller C, Greil C, Hackanson B, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Döhner K, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S, Lübbert M.

Blood. 2014 Mar 20;123(12):1883-6. doi: 10.1182/blood-2013-10-533844. Epub 2014 Feb 3.

PMID:
24493670
28.

Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.

van der Sluis I, Möricke A, Escherich G, von Stackelberg A, Holter W, Klingebiel T, Flotho C, Legien S, Tissing W, Bierings M, Guimbal-Schmolck C, Pichlmeier U, Kühnel HJ, Pieters R.

Haematologica. 2013 Nov;98(11):1697-701. doi: 10.3324/haematol.2013.090563. Epub 2013 Jun 10.

29.

Successful double umbilical cord blood transplantation for relapsed juvenile myelomonocytic leukemia.

Flotho C, Vraetz T, Lang P, Niemeyer CM, Strahm B.

Leukemia. 2013 Apr;27(4):988-9. doi: 10.1038/leu.2012.273. Epub 2012 Sep 24. No abstract available.

PMID:
23000834
30.

Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.

Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, Klingebiel T, Thol F, Schlegelberger B, Baumann I, Strahm B, Stary J, Locatelli F, Zecca M, Bergstraesser E, Dworzak M, van den Heuvel-Eibrink MM, De Moerloose B, Ogawa S, Niemeyer CM, Wlodarski MW; European Working Group of MDS in Childhood.

Blood. 2012 Mar 15;119(11):e96-9. doi: 10.1182/blood-2011-12-395087. Epub 2012 Jan 11.

PMID:
22238327
31.

Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A.

Wlodarski MW, Mötter J, Gorr TA, Olk-Batz C, Hasle H, Dworzak M, Niemeyer CM, Flotho C.

Blood. 2011 Oct 20;118(16):4490-1. doi: 10.1182/blood-2011-07-370684. No abstract available.

32.

Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia.

Ripperger T, Tauscher M, Praulich I, Pabst B, Teigler-Schlegel A, Yeoh A, Göhring G, Schlegelberger B, Flotho C, Niemeyer CM, Steinemann D.

Br J Haematol. 2011 Oct;155(2):209-17. doi: 10.1111/j.1365-2141.2011.08817.x. Epub 2011 Aug 18. Review.

PMID:
21848520
33.

Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.

Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle H, Zecca M, Stary J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM, Flotho C; European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS).

Blood. 2011 May 5;117(18):4871-80. doi: 10.1182/blood-2010-08-298968. Epub 2011 Mar 15.

PMID:
21406719
34.

Long-term outcome of hemizygous and heterozygous carriers of a germline GATA1 (G208R) mutation.

Dührsen U, Kratz CP, Flotho C, Lauenstein T, Bommer M, König E, Brittinger G, Heimpel H.

Ann Hematol. 2011 Mar;90(3):301-6. doi: 10.1007/s00277-010-1088-9. Epub 2010 Oct 5.

35.

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.

Nat Genet. 2010 Sep;42(9):794-800. doi: 10.1038/ng.641. Epub 2010 Aug 8.

36.

Clonal heterogeneity in childhood myelodysplastic syndromes--challenge for the detection of chromosomal imbalances by array-CGH.

Praulich I, Tauscher M, Göhring G, Glaser S, Hofmann W, Feurstein S, Flotho C, Lichter P, Niemeyer CM, Schlegelberger B, Steinemann D.

Genes Chromosomes Cancer. 2010 Oct;49(10):885-900. doi: 10.1002/gcc.20797.

PMID:
20589934
37.

Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?

Steinemann D, Tauscher M, Praulich I, Niemeyer CM, Flotho C, Schlegelberger B.

Haematologica. 2010 Sep;95(9):1616. doi: 10.3324/haematol.2010.024984. Epub 2010 May 11. No abstract available.

38.

Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?

Batz C, Hasle H, Bergsträsser E, van den Heuvel-Eibrink MM, Zecca M, Niemeyer CM, Flotho C; European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS).

Blood. 2010 Mar 25;115(12):2557-8. doi: 10.1182/blood-2009-12-260901. No abstract available.

39.

Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.

Bresolin S, Zecca M, Flotho C, Trentin L, Zangrando A, Sainati L, Stary J, de Moerloose B, Hasle H, Niemeyer CM, Te Kronnie G, Locatelli F, Basso G.

J Clin Oncol. 2010 Apr 10;28(11):1919-27. doi: 10.1200/JCO.2009.24.4426. Epub 2010 Mar 15.

PMID:
20231685
40.

Mutational analysis of SHOC2, a novel gene for Noonan-like syndrome, in JMML.

Flotho C, Batz C, Hasle H, Bergsträsser E, van den Heuvel-Eibrink MM, Zecca M, Niemeyer CM, Zenker M.

Blood. 2010 Jan 28;115(4):913. doi: 10.1182/blood-2009-10-250779. No abstract available.

41.

Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J, Schlegelberger B, Niemeyer CM, Flotho C.

Haematologica. 2010 Feb;95(2):320-3. doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16.

42.

Mutations of the Shwachman-Bodian-Diamond syndrome gene in patients presenting with refractory cytopenia--do we have to screen?

Karow A, Flotho C, Schneider M, Fliegauf M, Niemeyer CM; European Working Group of Myelodysplastic Syndromes in Childhood.

Haematologica. 2010 Apr;95(4):689-90. doi: 10.3324/haematol.2009.015008. Epub 2009 Nov 30. No abstract available.

43.

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM.

Blood. 2009 Aug 27;114(9):1859-63. doi: 10.1182/blood-2009-01-198416. Epub 2009 Jul 1.

44.

Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.

Yang Z, Kondo T, Voorhorst CS, Nabinger SC, Ndong L, Yin F, Chan EM, Yu M, Würstlin O, Kratz CP, Niemeyer CM, Flotho C, Hashino E, Chan RJ.

Mol Cell Biol. 2009 Aug;29(16):4376-93. doi: 10.1128/MCB.01330-08. Epub 2009 Jun 15.

45.

Methylation of the PTEN gene CpG island is infrequent in juvenile myelomonocytic leukemia: Comments on "PTEN deficiency is a common defect in juvenile myelomonocytic leukemia" [Leuk. Res. 2009;33:671-677 (Epub 2008 November 17)].

Batz C, Sandrock I, Niemeyer CM, Flotho C.

Leuk Res. 2009 Nov;33(11):1578-9; author reply 1580. doi: 10.1016/j.leukres.2009.04.040. Epub 2009 May 31. No abstract available.

PMID:
19487024
46.

Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.

Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM.

Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693. No abstract available.

PMID:
19299654
47.

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M.

Leukemia. 2009 Jun;23(6):1019-28. doi: 10.1038/leu.2008.397. Epub 2009 Feb 5.

PMID:
19194470
48.

Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations.

Flotho C, Kratz CP, Bergsträsser E, Hasle H, Starý J, Trebo M, van den Heuvel-Eibrink MM, Wójcik D, Zecca M, Locatelli F, Niemeyer CM; European Working Group of Myelodysplastic Syndromes in Childhood.

Blood. 2008 Jan 15;111(2):966-7; author reply 967-8. doi: 10.1182/blood-2007-09-111831. No abstract available.

49.

How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia.

Flotho C, Kratz CP, Niemeyer CM.

Haematologica. 2007 Nov;92(11):1441-6. Review. No abstract available.

50.

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

Archambeault S, Flores NJ, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RP, Niemeyer CM, Bader P, Loh ML.

Blood. 2008 Feb 1;111(3):1124-7. Epub 2007 Nov 13.

Supplemental Content

Loading ...
Support Center